Traditional Chinese medicine composition for treating fatty liver, diabetes mellitus and abnormal liver function as well as preparation method and application of traditional Chinese medicine composition

Abstract

The invention discloses a traditional Chinese medicine composition for treating fatty liver, diabetes mellitus and abnormal liver function, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9 to 15 parts of herba artemisiae annuae, 3 to 6 parts of radix et rhizoma rhei, 9 to 12 parts of fructus gardeniae, 3 to 6 parts of tetrapanax papyriferus, 12 to 18 parts of herba polygoni avicularis, 9 to 15 parts of herba dianthi, 12 to 18 parts of rhizoma dioscoreae colletii, 15 to 21 parts of talc and 3 to 6 parts of radix glycyrrhizae. The traditional Chinese medicine composition can solve the problem of abnormal liver function caused by phlegm-damp-heat stasis-turbid stagnation, and component toxicity is reduced due to a simple prescription; the traditional Chinese medicine is mainly used for dredging liver and gallbladder stasis heat, and can eliminate phlegm damp-heat stasis turbidity from intestinal tracts and urethra, so that a good treatment effect on liver dysfunction is realized.

Description

Technical Field

[0001] The present invention belongs to the field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating fatty liver and diabetes combined with abnormal liver function, as well as a preparation method and application thereof. Background Art

[0002] Abnormal liver function refers to deviations from normal liver parameters. Common indicators and abnormalities include elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, elevated bilirubin, decreased serum albumin levels, and coagulation disorders. The causes of abnormal liver function are as follows: 1. Viral infection is the most common cause, such as hepatitis A, B, C, D, and E. 2. Medications: Many medications can cause liver damage, including antibiotics, antipyretics, analgesics, anticonvulsants, and lipid-lowering drugs. 3. Alcohol: Long-term, heavy drinking can lead to alcoholic liver disease, including alcoholic fatty liver disease, alcoholic hepatitis, and alcoholic cirrhosis. 4. Autoimmune diseases: Autoimmune hepatitis is an autoimmune-mediated liver disease in which the immune system mistakenly attacks liver cells, leading to abnormal liver function. 5. Other causes include fatty liver disease, which is closely associated with metabolic syndromes such as obesity, diabetes, and hyperlipidemia. Genetic factors can lead to abnormal metabolism of certain substances in the body, which accumulate in the liver and cause liver damage.

[0003] In the field of Traditional Chinese Medicine formulas for treating abnormal liver function, common prescriptions include: Xiaoyao Powder (soothes the liver and relieves depression, strengthens the spleen and nourishes blood), which is used for patients with liver depression and spleen deficiency in chronic hepatitis, early cirrhosis, and fatty liver; Longdan Xiegan Decoction (clears the liver and removes dampness), which is mainly used for patients with liver and gallbladder damp-heat in acute hepatitis and cholecystitis; Yinchenhao Decoction (clears heat, removes dampness, and reduces jaundice), which is used for patients with damp-heat jaundice in acute cholecystitis and biliary tract infections; Chaihu Shugan Powder (soothes the liver and regulates qi), which is used for patients with liver depression and qi stagnation in chronic hepatitis, cirrhosis, and early cholecystitis; Biejia Jianwan (softens and dissipates nodules, promotes blood circulation and removes blood stasis), which is used for patients with liver yin deficiency in cirrhosis and hepatosplenomegaly; Xiaochaihu Decoction (harmonizes the Shaoyang meridian), which is used for patients with Shaoyang deficiency in chronic nephritis and cholecystitis; and Fufang Biejia Ruangan Pian. These prescriptions are primarily suitable for patients with liver fibrosis and early cirrhosis. However, all of these prescriptions require syndrome differentiation and treatment. At the same time, the combination may damage the stomach or have certain toxicity. Summary of the Invention

[0004] In order to reduce the toxicity and side effects of the existing prescriptions for treating abnormal liver function while ensuring the good efficacy of the prescriptions, the present invention provides a traditional Chinese medicine composition for treating fatty liver, diabetes and abnormal liver function, which can solve the problem of abnormal liver function caused by "phlegm, dampness, heat, blood stasis and stagnation".

[0005] The technical solutions of the present invention are as follows:

[0006] The invention provides a traditional Chinese medicine composition for treating fatty liver and diabetes combined with abnormal liver function. The traditional Chinese medicine composition comprises the following raw materials by weight: 9-15 parts of artemisia annua, 3-6 parts of rhubarb, 9-12 parts of gardenia, 3-6 parts of tongcao, 12-18 parts of scutellaria baicalensis, 9-15 parts of dianthus fragrans, 12-18 parts of radix polygoni multiflori, 15-21 parts of talc and 3-6 parts of liquorice.

[0007] Furthermore, the Chinese medicine composition further comprises the following raw materials in parts by weight: 6-9 parts of bupleurum and 8-12 parts of schisandra chinensis.

[0008] The present invention also provides a use of a traditional Chinese medicine composition in treating fatty liver and diabetes combined with abnormal liver function. The traditional Chinese medicine composition may or may not contain pharmaceutically usable excipients.

[0009] Furthermore, the dosage form of the Chinese medicine composition is tablets, capsules, oral liquid or granules.

[0010] The present invention also provides a method for preparing a traditional Chinese medicine composition for treating fatty liver and diabetes combined with abnormal liver function, comprising the following steps:

[0011] (1) Rhubarb and Dianthus superbus are decocted for at least 30 minutes, and the decocted medicinal liquid is subjected to alcohol extraction to obtain an extract;

[0012] (2) The remaining ingredients were decocted for at least 15 minutes to obtain a decoction;

[0013] (3) mixing the extract of rhubarb and dianthus obtained after alcohol extraction in step (1) and the mixed decoction obtained in step (2) to form a traditional Chinese medicine composition.

[0014] Compared with the prior art, the beneficial effects of the present invention are embodied in:

[0015] The traditional Chinese medicine composition provided by the present invention is used to solve the problem of abnormal liver function caused by "phlegm, dampness, heat, blood stasis and turbidity stagnation". The simplified prescription reduces the toxicity of the ingredients. The prescription focuses on "clearing" and clearing away the blood stasis and heat in the liver and gallbladder, and can eliminate phlegm, dampness, heat, blood stasis and turbidity from the intestines and urethra, thereby achieving a good therapeutic effect on abnormal liver function.

[0016] The dosage of rhubarb in the present invention is greatly reduced compared with the existing compound prescriptions. A small dose of rhubarb combined with long-term decoction can achieve extremely good effects of promoting blood circulation and removing blood stasis, strengthening the stomach and eliminating accumulation, and has a bidirectional regulating effect on laxative effect. In addition, the toxic and side effects are significantly reduced, avoiding problems such as diarrhea, electrolyte imbalance and intestinal melanosis caused by uncontrolled rhubarb dosage.

[0017] In the Chinese medicine composition of the present invention, Artemisia annua is combined with Rhubarb and Gardenia jasminoides to clear the intestines; and Herba Anemarrhenae, Radix Dichroae, Radix Polygoni Multiflori and Dianthus chinensis are combined to clear the urinary tract.

[0018] Artemisia annua is the main drug, which has the effects of clearing away dampness and heat from the liver and gallbladder, expelling pathogens and relieving jaundice, protecting the liver and lowering enzymes.

[0019] Rhubarb, Gardenia, Talcum, and Radix Dioscoreae serve as assistant herbs. Rhubarb promotes blood circulation and dissipates blood stasis, strengthens the stomach, eliminates stagnation, improves liver microcirculation, and regulates bowel movements in both directions. Gardenia clears damp-heat in the triple energizer, promotes bile secretion and reduces jaundice, and helps Artemisia annua dissolve stagnant heat in the liver meridian. Talcum acts as a diuretic and relieves stranguria, guiding phlegm, damp-heat, stasis, and turbidity through urine, alleviating the burden on the liver. Radix Dioscoreae separates the clear from the turbid, targeting the lipid metabolism disorders associated with phlegm, damp-heat, turbidity, and stasis. These four assistant herbs work together with the main herbs to protect the liver and reduce enzyme levels, enhancing efficacy.

[0020] Dianthus, Polygonum multiflorum, and Smilax glabra are adjuvants. The combination of Dianthus and Polygonum multiflorum can achieve diuresis and relieve stranguria, while assisting talc in strengthening the excretion of phlegm, dampness, heat, and stasis. Smilax glabra can clear and move upward, dredge the meridians and promote diuresis, and prevent the other drugs from settling too much and damaging the stomach.

[0021] Licorice is an adjuvant drug that can work with talcum powder to guide phlegm, dampness, heat, blood stasis and turbidity out of the urine, and can also protect the stomach and harmonize the other drugs.

[0022] The addition of bupleurum and schisandra chinensis in the present invention can cooperate with the above-mentioned medicines. Bupleurum soothes the liver, and schisandra chinensis restrains the liver, which is in line with the pathogenesis, and both attack and supplement are used to protect the liver and lower enzymes, improve abnormal liver function and abnormal liver function caused by fatty liver and glucose metabolism disorders, and achieve better efficacy. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Schematic diagram of HE staining of the normal group, diabetic model group and traditional Chinese medicine treatment group in Example 10. DETAILED DESCRIPTION

[0024] The following is a clear and complete description of the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts are within the scope of protection of the present invention.

[0025] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0026] The experimental methods in the following examples are conventional methods unless otherwise specified.

[0027] To verify the efficacy of the Chinese medicine composition of the present invention, the inventors conducted the following experiment using a medicinal solution prepared according to the ratio and composition of the Chinese medicine composition provided in Example 1, but this experiment does not constitute any limitation to the technical solution of the present invention.

[0028] Example 1

[0029] The present embodiment provides a traditional Chinese medicine composition for treating fatty liver and diabetes combined with abnormal liver function. The traditional Chinese medicine composition comprises the following raw materials by weight: 9 parts of Artemisia annua, 3 parts of Rhubarb, 9 parts of Gardenia jasminoides, 3 parts of Smilax glabra, 12 parts of Polygonum multiflorum, 9 parts of Dianthus chinensis, 12 parts of Trichosanthes kirilowii, 15 parts of Talc, and 3 parts of Licorice.

[0030] The preparation method of the above-mentioned Chinese medicine composition comprises the following steps:

[0031] (1) Rhubarb and Dianthus superbus are decocted for at least 30 minutes, and the decocted medicinal liquid is subjected to alcohol extraction to obtain an extract;

[0032] (2) The remaining ingredients were decocted for at least 15 minutes to obtain a decoction;

[0033] (3) mixing the extract of rhubarb and dianthus obtained after alcohol extraction in step (1) and the mixed decoction obtained in step (2) to form a traditional Chinese medicine composition.

[0034] Example 2

[0035] The difference between Example 2 and Example 1 is that the weight parts of the ingredients of the traditional Chinese medicine composition are different, specifically as follows: the traditional Chinese medicine composition includes 15 parts of Artemisia annua, 6 parts of Rhubarb, 12 parts of Gardenia jasminoides, 6 parts of Smilax glabra, 18 parts of Polygonum multiflorum, 15 parts of Dianthus chinensis, 18 parts of Trichosanthes kirilowii, 21 parts of talc and 6 parts of licorice.

[0036] Example 3

[0037] The difference between Example 3 and Example 1 is that the weight parts of the components of the traditional Chinese medicine composition are different, specifically as follows: the traditional Chinese medicine composition includes 10 parts of Artemisia annua, 5 parts of Rhubarb, 10 parts of Gardenia jasminoides, 4 parts of Smilax china, 16 parts of Polygonum multiflorum, 12 parts of Dianthus chinensis, 14 parts of Trichosanthes kirilowii, 16 parts of talc and 4 parts of licorice.

[0038] Example 4

[0039] The difference between Example 4 and Example 1 is that the weight parts of the ingredients of the traditional Chinese medicine composition are different, specifically as follows: the traditional Chinese medicine composition includes 12 parts of Artemisia annua, 4 parts of rhubarb, 11 parts of Gardenia jasminoides, 5 parts of Smilax glabra, 14 parts of Polygonum multiflorum, 10 parts of Dianthus chinensis, 15 parts of Trichosanthes kirilowii, 20 parts of talc, 5 parts of licorice, 6 parts of Bupleurum chinense and 8 parts of Schisandra chinensis.

[0040] Example 5

[0041] The difference between Example 5 and Example 1 is that the weight parts of the components of the traditional Chinese medicine composition are different, specifically as follows: the traditional Chinese medicine composition includes 9 parts of Artemisia annua, 6 parts of Rhubarb, 9 parts of Gardenia jasminoides, 3 parts of Smilax glabra, 18 parts of Polygonum multiflorum, 9 parts of Dianthus chinensis, 13 parts of Trichosanthes kirilowii, 14 parts of talc, 6 parts of Licorice, 9 parts of Bupleurum chinense and 12 parts of Schisandra chinensis.

[0042] Example 6

[0043] The difference between Example 4 and Example 1 is that the weight parts of the components of the traditional Chinese medicine composition are different, specifically as follows: the traditional Chinese medicine composition includes 11 parts of Artemisia annua, 3 parts of rhubarb, 12 parts of Gardenia jasminoides, 6 parts of Smilax glabra, 13 parts of Polygonum multiflorum, 10 parts of Dianthus chinensis, 18 parts of Trichosanthes kirilowii, 21 parts of talc, 3 parts of licorice, 9 parts of Bupleurum chinense and 10 parts of Schisandra chinensis.

[0044] Animal experiments

[0045] In this study, 50 SPF female Wistar rats (2.5 months old, weighing 180-200 g) were used as experimental subjects. They were adaptively raised under temperature (24.0±1.0) and relative humidity 55-65% for 7 days. During this period, the animals were allowed to drink water and eat freely. Ten rats were randomly selected according to their body weight as the normal group, and the remaining 40 rats were fed a high-fat and high-sugar diet (the high-fat diet formula was 10% lard, 15% sucrose, 4% cholesterol, 10% egg yolk powder, 0.3% bile salt, 60.7 % basal feed); after 6 weeks, fasting for 8-12 h, STZ was injected intraperitoneally to establish a type 2 diabetes model. After intraperitoneal injection of STZ on the first day, STZ was injected intraperitoneally again 72 h later. Random blood glucose was measured by glucose oxidase method on the 5th and 7th days after the second STZ injection (fasting for 8 h). The standard was that two consecutive random blood glucose measurements were greater than 16.7 mmol / L. 30 diabetic model rats were screened and stratified by blood glucose. They were randomly divided into model group (10 ml / Kg·d -1 ), Chinese medicine group (gavage with the Chinese medicine composition provided in Example 1 of the present invention (9 parts of Artemisia annua, 3 parts of Rhubarb, 9 parts of Gardenia jasminoides, 3 parts of Smilax glabra, 12 parts of Polygonum multiflorum, 9 parts of Dianthus chinensis, 12 parts of Trichosanthes kirilowii, 15 parts of Talc and 3 parts of Licorice), metformin group (Glucophage, 100 mg / 1 kg·d -1 Ten rats were gavaged in each group at a dose of 1 mL / 100 g twice daily, starting at 8 a.m. and 5 p.m., respectively. After 50 consecutive days of administration, the rats were fasted but not watered the night before sampling. The rats were weighed and anesthetized at 8 a.m. the next day. Blood was collected via the abdominal aorta and centrifuged at 4°C to prepare serum, which was then stored at -80°C for testing of blood glucose, liver function, and four liver fibrosis parameters (HA, LN, PⅢNP, and CⅣ). Meanwhile, the livers and other tissues and organs of the rats in each group were quickly removed. One portion of the liver was placed in a 1.5 mL EP tube at a rate of 100 mg per tube and quickly frozen in liquid nitrogen. The remaining portion was then quickly transferred to a -80°C freezer for RT-PCR and Western Blot. The remaining portion was immersed in 4% paraformaldehyde for HE staining.

[0046] Example 7 Four indicators of liver function and liver fibrosis in rats in each group after treatment in animal experiments

[0047] The results are shown in Table 1. Compared with the normal group, the indicators ALT, AST, HA, PCⅢ, and LN in the model group were significantly increased (P<0.05), and CⅣ in the model group was increased, but not statistically significant (P>0.05); compared with the model group, the indicators ALT, AST, and HA in the traditional Chinese medicine group were significantly decreased (P<0.05); compared with the model group, the indicators HA, PCⅢ, and CⅣ in the traditional Chinese medicine group were significantly decreased (P<0.05); compared with the model group, the indicator LN in the metformin group was significantly increased (P<0.05), and LN in the traditional Chinese medicine group was decreased, but not statistically significant (P>0.05).

[0048] Table 1 Comparison of liver function and liver fibrosis in rats in each group after treatment

[0049]

[0050] Note: a. Compared with the model group, *P<0.05 Note: b. Compared with the normal group, #P<0.05

[0051] Example 8 Expression of α-SMA, TGF-β1, SMAD2, SMAD3, and COL-1 mRNA in rats in each group after treatment in the animal experiment

[0052] The results are shown in Table 2. Compared with the normal group, the model group had significantly increased α-SMA, TGF-β1, SMAD2, SMAD3, and COL-1 mRNA expression levels (P < 0.05). Compared with the model group, the TCM group had significantly decreased α-SMA, TGF-β1, SMAD2, SMAD3, and COL-1 mRNA levels (P < 0.05). Compared with the model group, the metformin group had significantly decreased TGF-β1, SMAD2, SMAD3, and COL-1 mRNA levels (P < 0.05). TGF-β1 also decreased, but the decrease was not statistically significant (P > 0.05).

[0053] Table 2 Expression of α-SMA, TGF-β1, SMAD2, SMAD3 and COL-1 mRNA in rats of each group after treatment ( n=8)

[0054] Note: a. Compared with the model group, *P<0.05 Note: b. Compared with the normal group, #P<0.05.

[0055] Example 9 Expression of TGF-β1 and SMAD2 proteins in rats in each group after treatment in animal experiments

[0056] As shown in Table 3 below, compared with the normal group, the expressions of TGF-β1 and SMAD2 in the model group were significantly increased; compared with the model group, the expressions of TGF-β1 and SMAD2 in the Chinese medicine group and the metformin group were significantly decreased (P<0.05).

[0057] Table 3 Expression of TGF-β1 and SMAD2 proteins in rats in each group after treatment ( n=8)

[0058]

[0059] Note: a. Compared with the model group, *P<0.05 Note: b. Compared with the normal group, #P<0.05.

[0060] Example 10

[0061] like Figure 1 HE staining of liver tissue showed that the normal group showed intact and clear liver tissue (including the central venous and portal areas), with uniform hepatocyte size and no degeneration or necrosis. The model group showed disorganized hepatocytes, enlarged sinusoids, extensive vacuolar degeneration, disrupted lobular architecture, hyperplasia of connective tissue in the portal areas, and abnormal morphology and structure of the central vein and portal areas. In the TCM prescription group, liver tissue structure remained relatively clear in both the central venous and portal areas, with significantly improved hepatic cord structure and sinusoids compared to the model group.

[0062] Clinical trials

[0063] Example 11

[0064] To verify the efficacy of the Chinese medicine composition provided by the present invention, the inventors conducted clinical trials on the Chinese medicine composition (medicinal solution) prepared according to the method of Example 1 above, but this experiment does not constitute any limitation to the technical solution of the present invention.

[0065] Case of diabetes combined with liver damage: Lin xx, male, age, 37 years old, weight 83.5 kg, on April 25, 2024, examination showed aspartate aminotransferase (AST): 59 U / L (10-40 U / L), alanine aminotransferase (ALT) 141 U / L (5-45 U / L), r-glutamyl transpeptidase (rGGT) 108 U / L (0-70 U / L), neutral fat 452 mg% (35-149 mg%), blood glucose 427 mg% (70-110 mg%), glycosylated hemoglobin 11.3%, C-reactive protein 4.4 (0.7-3.5), other indicators were normal. 30 doses of Chinese medicine were taken. Among them, 18 doses of Dendrobium mixture 1 (self-developed diabetes prescription) and 12 doses of prescription 2 (the formula Chinese medicine composition of Example 1 of the present invention) were taken in the order of 3+6+3+6+3+6+3, 1 dose per day, each dose was decocted twice, and each decoction was more than 30 minutes. On June 13, 2024, the aspartate aminotransferase was 41U / L, the alanine aminotransferase was 79U / L, the r-glutamyl transpeptidase was 60U / L, the neutral fat was 231mg%, the blood sugar was 253mg%, the C-reactive protein was 2.5, the glycosylated hemoglobin was 10.3%, and the body weight was 80.5kg.

[0066] Case of fatty liver combined with liver damage: Ms. Weng, female, 50 years old, visited the hospital on March 10, 2025. Routine blood biochemistry showed: alanine aminotransferase (ALT) 104.3U / L (2-50U / L), aspartate aminotransferase (AST) 60.6U / L (0-50U / L), r-glutamyl transpeptidase (rGGT) 71.2U / L (0-50U / L), total cholesterol 7.52mmol / L (0-5.20mmol / L), triglycerides 2.88mmol / L (0-1:71mmol / L), low-density lipoprotein LDL-C 4.97mmol / L (0-3.3mmol / L), APOB1.52mmol / L (0.6-1.14mmol / L), and other indicators were within the normal range.

[0067] Prescribe 6 doses of the Chinese medicine composition of Example 1 of the present invention, take 3 doses first and then take 3 doses after 3-5 days, and take 20 mg / tablet of atorvastatin in combination, 1 tablet per day;

[0068] On March 24, routine blood biochemistry was reviewed: alanine aminotransferase (ALT) 90.6U / L, aspartate aminotransferase (AST) 56.8U / L, r-glutamyl transpeptidase (rGGT) 53.2U / L, total cholesterol 4.2mmol / L, triglycerides 2.33mmol / L, low-density lipoprotein LDL-C 2.32mmol / L, APOB 1.15mmol / L. The remaining indicators were all within the normal range. In view of the fact that total cholesterol, triglycerides, and LDL-C had dropped to the normal range, the patient was advised to reduce the dose of atorvastatin by half, that is, 10mg / day, once a day, and continue to take 6 doses of the Chinese medicine composition of Example 1 of the present invention, taking 3 doses first and then taking 3 doses after an interval of 3-5 days;

[0069] On April 8, routine blood biochemistry was rechecked: alanine aminotransferase (ALT) 75.U / L, aspartate aminotransferase (AST) 47.6U / L, r-glutamyl transpeptidase (rGGT) 48.7U / L, total cholesterol 4.25mmol / L, triglycerides 1.4mmol / L, low-density lipoprotein LDL-C 2.8mmol / L, APOB 1.12. The remaining indicators were all within the normal range. The patient was asked to take 9 doses of the Chinese medicine composition of Example 1 of the present invention and then recheck;

[0070] On April 20, routine blood biochemistry was reviewed: alanine aminotransferase (ALT) 48.2U / L, aspartate aminotransferase (AST) 42.8U / L, r-glutamyl transpeptidase (rGGT) 40.2U / L, total cholesterol 4.2mmol / L, triglycerides 1.3mmol / L, low-density lipoprotein LDL-C 2.4mmol / L, APOB 1.08, i.e., all of the above abnormal indicators returned to normal. After taking the Chinese medicine composition provided by the present invention, the patient's blood pressure dropped from 150-160 / 90-95mmHg to 130-140 / 75-80mmHg, and symptoms such as numbness and swelling of the hands and feet, swelling of the face, and insomnia were all improved, without any discomfort symptoms, and all routine biochemical indicators returned to normal.

[0071] The above descriptions are merely embodiments of the present invention and are not intended to limit the patent scope of the present invention. Any equivalent structure or equivalent process transformation made using the contents of the present invention specification, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.

Claims

1. A Chinese medicine composition for treating fatty liver and diabetes combined with abnormal liver function, characterized by: The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 9-15 parts of Artemisia annua, 3-6 parts of Rhubarb, 9-12 parts of Gardenia jasminoides, 3-6 parts of Smilax glabra, 12-18 parts of Polygonum multiflorum, 9-15 parts of Dianthus bistorta, 12-18 parts of Radix Dioscoreae, 15-21 parts of Talc and 3-6 parts of Licorice.

2. The Chinese medicine composition according to claim 1, wherein: The traditional Chinese medicine composition further comprises the following raw materials in parts by weight: 6-9 parts of bupleurum and 8-12 parts of schisandra chinensis.

3. Use of a traditional Chinese medicine composition according to claim 1 or 2 in the treatment of fatty liver and diabetes combined with abnormal liver function, characterized in that: The Chinese medicine composition may or may not contain pharmaceutically acceptable excipients.

4. The use according to claim 4, characterized in that: The dosage form of the Chinese medicine composition is tablets, capsules, oral liquid or granules.

5. A method for preparing a traditional Chinese medicine composition for treating fatty liver and diabetes combined with abnormal liver function according to claim 1 or 2, characterized in that: The steps include: (1) Rhubarb and Dianthus superbus are decocted for at least 30 minutes, and the decocted medicinal liquid is subjected to alcohol extraction to obtain an extract; (2) The remaining ingredients were decocted for at least 15 minutes to obtain a decoction; (3) mixing the extract of rhubarb and dianthus obtained after alcohol extraction in step (1) and the mixed decoction obtained in step (2) to form a traditional Chinese medicine composition.

Images